Document is current

Article History

Received: 2 November 2023

Accepted: 14 October 2024

First Online: 30 October 2024

Declarations

:

: Not applicable as these were de-identified samples so consent was not possible and waiver was not required. Furthermore, the study was approved by the IRB.

: All authors consented for publication.

: Meghan M. Lynch reports no conflicts of interest in this work. Rusul Almarayaty reports no conflicts of interest in this work. Farres Obeidin reports no conflicts of interest in this work. Borislav A. Alexiev reports no conflicts of interest in this work. Eleanor Chen reports no conflicts of interest in this work. Pedro Vivieros receives consulting, advisory from, Deciphera and speakers fee from Springworks. Brett A. Schroeder reports no conflicts of interest in this work. Kelly Hudkins reports no conflicts of interest in this work. Timothy M. Fan reports the following conflicts of interest: consulting or advisory role with Volition, research funding from Ankyra Therapeutics, and intellectual property through SHIELDT3. Mary W. Redman reports no conflicts of interest in this work. Kelsey K. Baker reports no conflicts of interest in this work. George Jour reports no conflicts of interest in this work. Lee D. Cranmer receives research funding (paid to institution) from AADI Biosciences, Avacta, Merck, Gradalis, Inhibrx, Monopar, Eli Lilly, Exelixis, Boehringer Ingelheim. He has received consulting, advisory and speaker fees from AADi Biosciences, Boehringer Ingelheim, Deciphera and Avacta. Dr. Cranmer’s work is supported, in part, by the Curt and Elizabeth Anderson Endowed Professorship in Sarcoma Research at the University of Washington. Seth M. Pollack receives research funding from Obsidian Therapeutics. He receives consulting, advisory and speaker fees from Bayer, Deciphera, Springworks, Sensei Therapeutics, Aadi Therapeutics, and Epizyme.